Finanzen von Bruker Corporation (BRKR)BRKRBruker Corporation

Bruker Corporation (BRKR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product, accounting for 79.2% of total sales, equivalent to $663.70M. Other significant revenue streams include Product And Service Other and Service and other revenue. Understanding this composition is critical for investors evaluating how BRKR navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Bruker Corporation maintains a gross margin of 49.65%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 9.78%, while the net margin is -6.07%. These profitability ratios, combined with a Return on Equity (ROE) of -5.11%, provide a clear picture of how effectively BRKR converts its operational activities into shareholder value.

In the context of the broader market, BRKR competes directly with industry leaders such as QGEN and SNN. With a market capitalization of $8.79B, it holds a significant position in the sector. When comparing efficiency, BRKR's gross margin of 49.65% stands against QGEN's 62.41% and SNN's 70.91%. Such benchmarking helps identify whether Bruker Corporation is trading at a premium or discount relative to its financial performance.

Bruker reported a revenue of $838.5 million in Q2 2026, a 5.2% increase from the previous quarter, but faced a net income loss of $62.9 million, reflecting significant earnings volatility.